Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 87
Filter
1.
Peptides ; 108: 34-45, 2018 10.
Article in English | MEDLINE | ID: mdl-30179653

ABSTRACT

Protease inhibition has become a new possible approach in the inflammatory bowel disease (IBD) therapy. A serine exopeptidase, dipeptidyl peptidase IV (DPP IV) is responsible for inactivation of incretin hormone, glucagon-like peptide 2 (GLP-2), a potent stimulator of intestinal epithelium regeneration and growth. Recently we showed that the novel peptide analog of endomorphin-2, EMDB-1 (Tyr-Pro-D-ClPhe-Phe-NH2) is a potent blocker of DPP IV and exhibits an anti-inflammatory activity in vivo. The aim of this study was to design, synthesize and characterize the therapeutic activity and mechanism of action of a series of novel EMDB-1 analogs. The inhibitory potential of all peptides was evaluated using the fluorometric screening assay employing Gly-Pro-Aminomethylcoumarin (AMC) to measure DPP IV activity. Consequently, one compound, namely DI-1 was selected and its therapeutic activity evaluated using mouse models of experimental colitis (induced by TNBS and DSS). Macro- and microscopic score, ulcer score, colonic wall thickness as well as myeloperoxidase activity were measured. We showed that DI-1 blocks DPP IV in vitro (IC50 = 0.76 ± 0.04 nM) and attenuates acute, semichronic and relapsing TNBS- as well as DSS-induced colitis in mice after topical administration. Its anti-inflammatory action is associated with the increase of colonic GLP-2 but not GLP2 receptor or DPP IV expression. Our results validate DPP IV as a pharmacological target for the anti-IBD drugs and its inhibitors, such as DI-1, have the potential to become valuable anti-inflammatory therapeutics.


Subject(s)
Colitis/drug therapy , Dipeptidyl Peptidase 4/drug effects , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Disease Models, Animal , Peptides/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Colitis/enzymology , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Male , Mice , Mice, Inbred C57BL , Peptides/therapeutic use
2.
J Physiol Pharmacol ; 69(5)2018 Oct.
Article in English | MEDLINE | ID: mdl-30683828

ABSTRACT

Exposition to environmental factors is one of the major underlying causes in inflammatory bowel diseases (IBD), with several endogenous systems involved. Our aim was to characterize the impact of stress on the colitis development in relation to the endogenous opioid system (EOS) activity in mice. A unique mouse model of high and low activity of EOS (namely high (HA)/low (LA) stress-induced analgesia) was employed. Mice were bred using bidirectional selection and classified as HA or LA line based on the measurement of analgesia. Colitis was induced by instillation of trinitrobenzenesulfonic acid in 30% EtOH/0.9% NaCl. After 4 days, the macroscopic score was assessed and samples for molecular and histological studies were collected. To evaluate the influence of stress on colitis development, chronic mild stress (exposure to stress stimuli for 2 and 5 weeks) and acute stress (short restraint over 3 days) were applied before colitis induction. We observed a difference in the colitis development between non-stressed HA and LA mice, as indicated by macroscopic and ulcer scores. Acute stress improved colitis in HA mice but did not change the inflammation score in LA line as compared to respective non-stressed mice. Chronic mild stress had no influence on colitis in either of mouse lines. Our study supports the hypothesis that the activity of EOS may be crucial in IBD development. We also evidence that acute, but not chronic stress influenced IBD exacerbation, depending on EOS function.


Subject(s)
Colitis/etiology , Stress, Psychological/complications , Analgesia , Animals , Colitis/metabolism , Colitis/pathology , Disease Models, Animal , Male , Mice , Narcotic Antagonists/pharmacology , Peroxidase/metabolism , Stress, Psychological/metabolism , Trinitrobenzenesulfonic Acid
3.
Naunyn Schmiedebergs Arch Pharmacol ; 390(10): 1015-1027, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28710683

ABSTRACT

Cannabinoid type 2 (CB2) receptors are distributed in central and peripheral tissues, including immunocytes and the gastrointestinal (GI) tract, suggesting that CB2 receptor agonists represent potential therapeutics in GI inflammatory states. In this study, we investigated the effect of highly selective CB2 agonist, A836339, on the development of gastric lesions. We used two models of gastric ulcer (GU) induced by ethanol (EtOH) and diclofenac. To confirm the involvement of CB2 receptors, a selective CB2 antagonist, AM630 was used. Clinical parameters for gastroprotection were assessed based on inhibition of the gastric lesion area. To investigate the anti-inflammatory effect of A836339, the expression of TNF-α and IL-1ß was assessed. To establish the mechanism of gastroprotective action, catalase (CAT), superoxide dismutase (SOD) activity and H2O2 and glutathione (GSH) levels were measured. Moreover, expression of CB2 and cyclooxygenase-2 (COX-2) was characterized using immunohistochemistry (IHC). A836339 reduced ulcer index in a dose-dependent manner in both EtOH- and diclofenac-induced GU models. This effect was reversed by the CB2 antagonist AM630. Administration of A836339 reduced TNF-α and IL-1ß levels in gastric tissue. Furthermore, A836339 exhibited potent anti-oxidant activity, as demonstrated by reduced H2O2 levels and increased CAT and SOD activities. IHC studies revealed a co-localization of CB2 receptors and COX-2 in the gastric tissue. Activation of CB2 receptors exhibited gastroprotective effect through enhancement of anti-oxidative pathways in the stomach. Activation of CB2 receptors may thus become a novel therapeutic approach in the treatment of GU.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Inflammation Mediators/antagonists & inhibitors , Receptor, Cannabinoid, CB2/agonists , Stomach Ulcer/prevention & control , Thiazoles/therapeutic use , Animals , Anti-Ulcer Agents/pharmacology , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Inflammation Mediators/metabolism , Male , Mice , Mice, Inbred BALB C , Protective Agents/pharmacology , Protective Agents/therapeutic use , Stomach Ulcer/metabolism , Stomach Ulcer/pathology , Thiazoles/pharmacology , Treatment Outcome
4.
J Crohns Colitis ; 11(8): 988-998, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28333341

ABSTRACT

BACKGROUND AND AIMS: Pharmacological treatment and/or maintenance of remission in inflammatory bowel disease [IBD] is currently one of the biggest challenges in the field of gastroenterology. Here we aimed to assess the anti-inflammatory effect and the mechanism of action of sialorphin, the natural blocker of the endogenous opioid peptide-degrading enzymes neprilysin [NEP] and aminopeptidase N [APN], in mouse models of IBD and the changes in the expression of these enzymes in IBD patients. METHODS: We used two models of experimental colitis in mice [2,4,6-trinitrobenzene sulphonic acid [TNBS]- and dextran sulphate sodium [DSS]-induced]. Macroscopic score, ulcer score, colonic wall thickness, and myeloperoxidase [MPO] activity were recorded. Additionally, we measured the expression of NEP and APN in the colon of IBD patients and healthy controls. RESULTS: We showed that sialorphin attenuated acute, semichronic, and relapsing TNBS-induced colitis in mice after systemic administration, and its anti-inflammatory action is associated with mu and kappa opioid receptors. CONCLUSIONS: We show that indirect stimulation of opioid receptors by the blockade of NEP and APN is a promising pharmacological strategy for the treatment of IBD, and may become of greater importance than the use of classical opioid agonists.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Colitis/drug therapy , Peptides/administration & dosage , Receptors, Opioid, kappa/agonists , Receptors, Opioid, mu/agonists , Animals , Disease Models, Animal , Injections, Intraperitoneal , Male , Mice , Mice, Inbred BALB C
5.
J Crohns Colitis ; 8(9): 998-1009, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24530133

ABSTRACT

BACKGROUND AND AIMS: Pharmacological treatment and/or maintenance of remission in inflammatory bowel diseases (IBD) is currently one of the biggest challenge in the field of gastroenterology. Available therapies are mostly limited to overcoming the symptoms, but not the cause of the disease. Recently, the endocannabinoid system has been proposed as a novel target in the treatment of IBD. Here we aimed to assess the anti-inflammatory action of the novel fatty acid amide hydrolase (FAAH) inhibitor PF-3845 and its effect on the endocannabinoid and related lipid metabolism during the course of experimental colitis. METHODS: We used two models of experimental colitis in mice (TNBS- and DSS-induced) and additionally, we employed LC/MS/MS spectrometry to determine the changes in biolipid levels in the mouse colon during inflammation. RESULTS: We showed that the FAAH inhibitor PF-3845 reduced experimental TNBS-induced colitis in mice and its anti-inflammatory action is associated with altering the levels of selected biolipids (arachidonic and oleic acid derivatives, prostaglandins and biolipids containing glycine in the mouse colon). CONCLUSIONS: We show that FAAH is a promising pharmacological target and the FAAH-dependent biolipids play a major role in colitis. Our results highlight and promote therapeutic strategy based on targeting FAAH-dependent metabolic pathways in order to alleviate intestinal inflammation.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Cannabinoids/metabolism , Colitis, Ulcerative/drug therapy , Indoles/therapeutic use , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Amidohydrolases/metabolism , Animals , Colitis, Ulcerative/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Indoles/administration & dosage , Injections, Intraperitoneal , Male , Mice , Mice, Inbred C57BL , Piperidines/administration & dosage , Pyrazoles/administration & dosage , Pyridines/administration & dosage , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/antagonists & inhibitors , Receptor, Cannabinoid, CB2/metabolism , Treatment Outcome
6.
Oncogene ; 33(21): 2779-89, 2014 May 22.
Article in English | MEDLINE | ID: mdl-23792450

ABSTRACT

Integrin α3ß1 regulates adhesive interactions of cells with laminins and have a critical role in adhesion-dependent cellular responses. Here, we examined the role of α3ß1-integrin in ErbB2-dependent proliferation of breast cancer cells in three-dimensional laminin-rich extracellular matrix (3D lr-ECM). Depletion of α3ß1 in ErbB2-overexpressing breast cancer cells suppressed growth and restore cell polarity in 3D lr-ECM. The phenotype of α3ß1-depleted cells was reproduced upon depletion of tetraspanin CD151 and mirrored that of the cells treated with Herceptin, an established ErbB2 antagonist. Breast cancer cells expressing the α3ß1-CD151 complex have higher steady-state phosphorylation of ErbB2 and show enhanced dimerization of the protein when compared with α3ß1-/CD151-depleted cells. Furthermore, Herceptin-dependent dephosphorylation of ErbB2 was only observed in α3ß1-CD151-expressing cells. Importantly, the inhibitory activity of Herceptin was more pronounced when cells expressed both α3ß1 and CD151. We also found that the level of active RhoA was increased in α3ß1- and CD151-depleted cells and that Rho controls dimerization of ErbB2. Expression of α3ß1 alone did not have significant prognostic value in patients with invasive ductal carcinoma of the breast. However, expression of α3ß1 in combination with CD151 represented a more stringent indicator of poor survival than CD151 alone. Taken together, these results demonstrate that the α3ß1-CD151 complex has a critical regulatory role in ErbB2-dependent signalling and thereby may be involved in breast cancer progression.


Subject(s)
Breast Neoplasms/metabolism , Integrin alpha3beta1/metabolism , Receptor, ErbB-2/metabolism , Tetraspanin 24/metabolism , Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , Breast Neoplasms/mortality , Cell Line, Tumor , Cell Polarity , Female , Humans , Phosphorylation , Prognosis , Proportional Hazards Models , Protein Multimerization , Protein Processing, Post-Translational , Signal Transduction , Trastuzumab , rhoA GTP-Binding Protein
7.
Pol J Pathol ; 64(4): 268-75, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24375041

ABSTRACT

Loss of heterozygosity (LOH) co-deletion 1p/19q, MGMT promoter methylation and/or IDH1 mutation generally signify a better prognosis for patients with glioma. However, the influence of 1p/19q co-deletion and the LOH on other chromosomes in primary glioblastoma on survival is still debatable. The aim of our study was to identify LOH on chromosomes 1p, 19q, 9p, 10q, 13q, and 17p, and evaluate their impact either alone or 1p/19q co-deletion or by groups of LOH on the overall survival of 42 primary glioblastoma patients without an oligodendroglial component. These patients were additionally molecularly characterized for EGFR amplification, IDH1 mutations and TP53 mutations. We assessed their influence on the overall survival of glioblastoma patients. LOH in at least one of the loci on all examined chromosomes was detected in 65% of cases and was significantly associated with shorter overall survival (hazard ratio 3.07; 95% CI: 1.29-7.31, p = 0.006). 1p/19q co-deletion was infrequent (7.14%) and had no impact on overall survival. Our results indicate that in primary glioblastoma a specific LOH group analysis may be important for the prognosis. LOH 1p/19q co-deletion is rare in glioblastoma without an oligodendroglial component and has no impact on patient survival.


Subject(s)
Chromosomes, Human, Pair 19/genetics , Glioblastoma/genetics , Loss of Heterozygosity/genetics , Adult , Aged , Animals , Chromosome Deletion , Chromosomes, Human, Pair 1/genetics , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , ErbB Receptors/genetics , Female , Glioblastoma/mortality , Humans , Isocitrate Dehydrogenase/genetics , Kaplan-Meier Estimate , Male , Middle Aged , Mutation, Missense , Prognosis , Sequence Analysis, DNA , Sequence Deletion , Tumor Suppressor Protein p53/genetics , Young Adult
8.
Neoplasma ; 58(5): 430-5, 2011.
Article in English | MEDLINE | ID: mdl-21744997

ABSTRACT

Smac/DIABLO protein promotes caspase-dependent apoptosis by inhibition of inhibitor of apoptosis protein (IAP) family members. The role of Smac/DIABLO in breast cancer has not been yet established. Therefore, the aim of the study was to assess the expression of this protein in tumor cells from breast cancer patients. The expression of Smac/DIABLO was analyzed in 62 breast cancer patients by flow cytometry. The obtained results were compared with expression of this protein in benign breast tumor tissue, which served as the control (11 patients with fibroadenoma). Expression of caspase-3 proteins in breast cancer was also evaluated. Smac/DIABLO expression in breast cancer was correlated with clinical and pathological data. Although the expression of Smac/DIABLO protein was found in all examined samples of both the breast cancer and fibroadenoma patients, the median expression of Smac/Diablo in breast cancer was significantly lower than in the control (39.1% vs. 48.1%; p=0.0047). Smac/DIABLO expression correlated with expression of caspase-3 (p=0.000008). In pT1 breast cancer patients, expression of Smac/DIABLO protein was higher than in those with pT2-3 (p=0.02). Diffuse cancer infiltration significantly correlated with lower expression of Smac/DIABLO protein (p=0.02). Moreover, there was a loose correlation between low expression of Smac/DIABLO protein and cancer embolus in minor blood and lymphatic vessels (p=0.08). Our results indicate that expression of Smac/DIABLO inversely correlates with the tumor stage, which may suggest that this protein may play an important role in the breast cancer development.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/metabolism , Carcinoma, Lobular/pathology , Intracellular Signaling Peptides and Proteins/metabolism , Mitochondrial Proteins/metabolism , Adult , Aged , Aged, 80 and over , Apoptosis Regulatory Proteins , Case-Control Studies , Caspase 3/metabolism , Female , Fibroadenoma/metabolism , Fibroadenoma/pathology , Flow Cytometry , Humans , Middle Aged , Prognosis , Survival Rate
9.
Neoplasma ; 57(2): 95-101, 2010.
Article in English | MEDLINE | ID: mdl-20099971

ABSTRACT

The aim of the study was to analyze the expression of Nm23-H1 and maspin proteins in a series of colorectal adenocarcinoma and to assess their applicability as prognostic factors in this type of cancer. 102 specimens of colorectal carcinoma were analyzed by immunohistochemistry with the use of anti-Nm23-H1 and anti-maspin monoclonal antibodies. Cytoplasmic expression of Nm23-H1 and maspin was found in 90 of all investigated cases. In 60 cases maspin protein was found also in nucleus. Medium/high Nm23-H1 cytoplasmic expression level was associated with tubular type of adenocarcinoma with deeper invasion of cancer into intestinal wall (T3, T4) and presence of vascular invasion. Medium/high expression level of maspin was connected uniformly with bad prognostic features: low differentiation of tumors (G3), deeper invasion of cancer (T3, T4) presence of nodular and distant metastases, higher Astler-Coller stage (C1, C2, D) and presence of vascular invasion. No statistically significant associations between presence of nuclear maspin expression and any clinicopatological and biological features were stated. Cytoplasmic medium/high expression level of maspin but no Nm23-H1 and no presence of maspin nuclear expression was found as independent bad prognostic factor in the investigated group of patients. Measurement of level and cellular pattern of maspin expression could be valuable for predicting disease course in patients suffering from colorectal cancer.


Subject(s)
Adenocarcinoma/metabolism , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/metabolism , NM23 Nucleoside Diphosphate Kinases/metabolism , Serpins/metabolism , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Cell Nucleus/metabolism , Colorectal Neoplasms/pathology , Cytoplasm/metabolism , Female , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Prognosis
10.
Clin Exp Dermatol ; 34(5): 570-5, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19077101

ABSTRACT

BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus, characterized by inflammation and scarring skin lesions, with lymphocyte infiltration and vasodilation. Antimalarial drugs have beneficial therapeutic effects in DLE, partially resulting from their immunomodulating and photoprotective properties. The possible influence of these drugs on angiogenesis has not been previously evaluated. AIMS: To investigate the impact of chloroquine (CQ) treatment on the expression of vascular endothelial growth factor (VEGF, a major regulator of angiogenesis) and CD34 (a transmembrane glycoprotein expressed on endothelial cells and involved in tethering lymphocytes) in patients with DLE. METHODS: A 3-mm skin biopsy was taken from typical skin lesions in 10 people with DLE. Another biopsy was taken from the same area after 3 months of treatment with CQ (250 mg/day). Skin sections were stained with monoclonal antibodies directed against VEGF and CD34. The intensity of epidermal VEGF expression, and the number and area of CD34-positive dermal blood vessels were assessed. RESULTS: CQ treatment induced a reduction in epidermal VEGF expression. It also resulted in a significant decrease in the median number of CD34+ dermal blood vessels (from 219 to 125 vessels per mm(2)). Furthermore the median vessel area was significantly lowered from 9.76 x 10(6) to 6.92 x 10(6) mm(2) per mm(2) of the dermis. CONCLUSIONS: These results indicate that one beneficial effect of CQ treatment in DLE may be due to its antiangiogenic properties.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Chloroquine/therapeutic use , Lupus Erythematosus, Discoid/drug therapy , Neovascularization, Pathologic/prevention & control , Skin/blood supply , Adult , Antigens, CD34/metabolism , Female , Humans , Lupus Erythematosus, Discoid/metabolism , Male , Middle Aged , Neovascularization, Pathologic/metabolism , Skin/metabolism , Vascular Endothelial Growth Factor A/metabolism , Young Adult
11.
Br J Cancer ; 98(8): 1431-3, 2008 Apr 22.
Article in English | MEDLINE | ID: mdl-18349850

ABSTRACT

We screened 50 glioblastomas for P53 mutations. Five glioblastomas showed heterozygous mutations, while three were putatively heterozygous. Six of these eight glioblastomas showed elimination of wild-type P53 mRNA. These results strongly suggest that some sort of mechanism(s) favouring mutated over wild-type P53 mRNA exists in glioblastoma cells with heterozygous mutations of this gene.


Subject(s)
Brain Neoplasms/genetics , Genes, p53 , Glioblastoma/genetics , Mutation , RNA, Messenger/analysis , Tumor Suppressor Protein p53/genetics , Adolescent , Adult , Aged , Female , Humans , Loss of Heterozygosity , Male , Middle Aged , Promoter Regions, Genetic
12.
Histopathology ; 51(6): 829-36, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18042072

ABSTRACT

AIMS: cDNA microarrays have subclassified breast carcinomas into molecular subtypes with oestrogen receptor-alpha (ER) gene expression as a main marker. The aim was to compare ER expression in 97 patients with operable breast cancer estimated by real-time reverse transcriptase-polymerase chain reaction (real-time RT-PCR) and by routine immunohistochemistry, and to determine which method was reliable for molecular subtyping in relation to basal-type keratins and HER2 gene expression. METHODS AND RESULTS: Frozen tumour samples were analysed by real-time RT-PCR for the expression of ER, HER2, keratin 5 and keratin 17 genes. In a group of 27 tumours with a low level of ER mRNA (<1.00), there were eight ER+ cases as assessed by immunohistochemistry, and of 70 cases with a high level of ER mRNA (>or=1.00), 26 were ER- by immunohistochemistry (P = 0.003). Lack of prognostic relevance of ER mRNA level was demonstrated, whereas assessment by immunohistochemistry was related to clinical outcome. Expression of basal keratins and HER2 genes differed significantly between ER+ and ER- tumours based on immunohistochemistry, but not on mRNA level. CONCLUSIONS: These results throw doubt on the assessment of ER mRNA as a key factor in the molecular distinction between breast tumours.


Subject(s)
Breast Neoplasms/metabolism , Gene Expression , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysis , Receptors, Estrogen/biosynthesis , Breast Neoplasms/mortality , DNA Primers , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Middle Aged , Prognosis , Receptor, ErbB-2/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity
13.
Pol J Pathol ; 58(2): 79-85, 2007.
Article in English | MEDLINE | ID: mdl-17715673

ABSTRACT

We described the case of an unusual, complex genetic alteration in 57 year-old male patient with glioblastoma multiforme (GBM) with short survival (6 and half months). Alterations consisted of p53 mutation, LOH 10, LOH 17, LOH 19q and EGFR amplification. LOH1p, LOH 9 and LOH 13 were negative. Immunohistochemical study did not correlate with molecular results. The overexpression of TP53 protein and RB protein was detected only in small percentage of cells and interestingly the overexpression of EGFR was present only focally. Immnunostainings for PTEN, P16, PI3-K were negative. Additionally, we observed an overexpression of IGFB2 protein. This case indicates the accumulation of molecular changes in glioblastoma multiforme in patient with short survival.


Subject(s)
Brain Neoplasms/genetics , Chromosomes, Human, Pair 10 , Chromosomes, Human, Pair 17 , Chromosomes, Human, Pair 19 , ErbB Receptors/genetics , Glioblastoma/genetics , Mutation , Tumor Suppressor Protein p53/genetics , Biomarkers, Tumor/analysis , Brain Neoplasms/chemistry , Brain Neoplasms/pathology , Brain Neoplasms/therapy , Combined Modality Therapy , Fatal Outcome , Gene Amplification , Glioblastoma/chemistry , Glioblastoma/pathology , Glioblastoma/therapy , Humans , Immunoenzyme Techniques , Loss of Heterozygosity , Male , Middle Aged , Mutation, Missense
14.
Nucleosides Nucleotides Nucleic Acids ; 25(9-11): 1025-8, 2006.
Article in English | MEDLINE | ID: mdl-17065058

ABSTRACT

In the tested samples of sporadic breast cancer (100 cases), hypermethylation of CpG sequences located in ERalpha promoter was observed in 62 cases. It correlated with: (i) deficiency of ERalpha protein in 45%, (ii) hypermethylation of BRCA1 promoter in 95%, and (iii) nonmethylated E-cadherin promoter in 90%. Fifty-eight percent of the patients with nonmethylated E-cadherin promoter (56 cases) did not show metastasis to lymphatic nodes. The analysis of the methylation level of the promoter of ERalpha, BRCA1, and E-cadherin, frequently connected with their activity, shows that it can be an important parameter in the diagnosis and therapeutic strategies in sporadic breast cancer.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , CpG Islands , DNA Methylation , Genes, Tumor Suppressor , Promoter Regions, Genetic , Adult , Aged , Cadherins/genetics , Estrogen Receptor alpha/genetics , Female , Humans , Middle Aged , Neoplasm Metastasis
15.
Br J Cancer ; 95(1): 123-9, 2006 Jul 03.
Article in English | MEDLINE | ID: mdl-16755295

ABSTRACT

Breast cancer is a morphologically and clinically heterogeneous disease; however, it is less clear how risk factors relate to tumour features. We evaluated risk factors by tumour characteristics (histopathologic type, grade, size, and nodal status) in a population-based case-control of 2386 breast cancers and 2502 controls in Poland. Use of a novel extension of the polytomous logistic regression permitted simultaneous modelling of multiple tumour characteristics. Late age at first full-term birth was associated with increased risk of large (> 2 cm) tumours (odds ratios (95% confidence intervals) 1.19 (1.07-1.33) for a 5-year increase in age), but not smaller tumours (P for heterogeneity adjusting for other tumour features (Phet) = 0.007). On the other hand, multiparity was associated with reduced risk for small tumours (0.76 (0.68-0.86) per additional birth; Phet = 0.004). Consideration of all tumour characteristics simultaneously revealed that current or recent use of combined hormone replacement therapy was associated with risk of small (2.29 (1.66-3.15)) and grade 1 (3.36 (2.22-5.08)) tumours (Phet = 0.05 for size and 0.0008 for grade 1 vs 3), rather than specific histopathologic types (Phet = 0.63 for ductal vs lobular). Finally, elevated body mass index was associated with larger tumour size among both pre- and postmenopausal women (Phet = 0.05 and 0.0001, respectively). None of these relationships were explained by hormone receptor status of the tumours. In conclusion, these data support distinctive risk factor relationships by tumour characteristics of prognostic relevance. These findings might be useful in developing targeted prevention efforts.


Subject(s)
Breast Neoplasms/classification , Breast Neoplasms/diagnosis , Breast Neoplasms/epidemiology , Case-Control Studies , Female , Humans , Middle Aged , Models, Statistical , Neoplasm Invasiveness , Odds Ratio , Poland/epidemiology , Population Surveillance , Prognosis , Risk Factors
16.
J Exp Clin Cancer Res ; 25(1): 59-64, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16761619

ABSTRACT

The main objective of this retrospective study was to investigate relations between cyclin E and pathoclinical factors in patients with operable breast cancer. Expression of cyclin E was analyzed by immunohistochemistry in specimens of invasive ductal breast cancer tissue obtained from 189 women during radical mastectomy. Overall, 110 tumor samples were regarded to be cyclin E positive. Cyclin E expression was more often seen in tumors with: negative steroid receptor status (p<0.0001), higher proliferative index (p=0.0014), higher tumor grade (p=0.0017), and presence of HER2 (p=0.0171). With a median follow-up of 58 months, expression of cyclin E together with negative steroid receptor status determined poor prognosis with a 5-year cancer-specific survival rate of 58%. It differed significantly from a survival curve of cyclin E negative and steroid receptor positive patients (87%, p=0.0005). No significant difference was observed in comparison with survival of cyclin E positive and steroid receptor positive patients (68%, p=0.221). We demonstrated that cyclin E expression in breast cancer cells was associated with negative steroid receptor status, HER2 presence, higher tumor grade and higher proliferation index. Expression of cyclin E together with lack of steroid receptors determined poor prognosis.


Subject(s)
Breast Neoplasms/metabolism , Cyclin E/biosynthesis , Gene Expression Regulation, Neoplastic , Receptor, ErbB-2/biosynthesis , Adult , Aged , Aged, 80 and over , Breast Neoplasms/genetics , Disease Progression , Female , Humans , Middle Aged , Prognosis , Receptors, Steroid/metabolism , Retrospective Studies
18.
Breast Cancer Res Treat ; 99(1): 71-6, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16541315

ABSTRACT

We identified 4316 unselected incident cases of early-onset breast cancers (<51 ears of age at diagnosis) in 18 Polish hospitals between 1996 and 2003. We were able to obtain a blood sample for DNA analysis from 3472 of these (80.4%). All cases were tested for the presence of three founder mutations in BRCA1. The proportion of cases with a BRCA1 mutation was 5.7%. The hereditary proportions were higher than this for women with breast cancer diagnosed before age 40 (9%), for women with cancer of medullary or atypical medullary histology (28%), for those with bilateral cancer (29%) or with a family history of breast or ovarian cancer (13%). It is reasonable to offer genetic testing to women with early-onset breast cancer in Poland.


Subject(s)
BRCA1 Protein/biosynthesis , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Genes, BRCA1 , Genetic Predisposition to Disease , Mutation , Adult , Breast Neoplasms/metabolism , DNA Mutational Analysis , Female , Humans , Middle Aged , Models, Statistical , Poland , Prospective Studies
19.
Eur J Surg Oncol ; 32(2): 153-7, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16360296

ABSTRACT

AIMS: WWOX is a tumour suppressor gene involved in various tumours including breast cancer. High chromosomal abnormalities in a genomic region spanned by WWOX are associated with the fact that this gene covers approximately 1 million base pairs of the second most affected among common chromosomal fragile sites FRA16D. We evaluated WWOX expression levels in breast cancer samples in association with diagnostics-prognostics markers. METHODS: We performed quantitative real-time RT-PCR to analyse levels of expression of WWOX in 132 cases of breast cancer. We evaluated the relationship between WWOX mRNA levels, clinico-pathological factors, expression of aberrant WWOXDelta6-8 mRNA and other cancer related genes. RESULTS: Expression of WWOX was higher in patients younger than 50 years old, in ER and PR positive tumours vs negative for those receptors and tumours without lymph node metastasis vs LN+. WWOX mRNA levels were also higher in tumours with higher apoptotic index (Bcl2/Bax ratio). Negative associations were found between WWOX expression and cytokeratins 5/6 and 17 (P<0.05). High level expression of WWOX was also associated with better disease free survival. Presence of WWOXDelta6-8 transcripts were accompanied with lower WWOX wild type mRNA level. CONCLUSIONS: Reduced WWOX expression commonly observed in various neoplasias in cases of breast cancer is associated with markers of bad prognosis. Our findings reveal additional evidence that WWOX may be involved in steroid (estrogens) metabolism and signaling pathways. WWOX can be considered as a new target for gene therapy development due to the association of high WWOX expression with improved disease free survival.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Oxidoreductases/genetics , Adult , Age Factors , Aged , Aged, 80 and over , Analysis of Variance , Apoptosis/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Disease Progression , Disease-Free Survival , Estrogen Receptor alpha/metabolism , Female , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Oxidoreductases/metabolism , Poland , Prognosis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Progesterone/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Suppressor Proteins , WW Domain-Containing Oxidoreductase
20.
Br J Dermatol ; 153(4): 833-7, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16181471

ABSTRACT

Richter syndrome (RS) is a transformation to high-grade non-Hodgkin lymphoma in patients with chronic lymphocytic leukaemia (CLL). RS may develop in lymph nodes or rarely extranodally. Skin localization of RS has been described in only a few cases. We present a 77-year-old woman who developed isolated diffuse large B-cell lymphoma (LBCL) in the skin of the nose without any other symptoms of RS. The LBCL in the skin was clonally distinct from the original bone marrow CLL cells. Moreover, LBCL cells were positive for LMP-1 segment of Epstein-Barr virus and overexpressed p53 protein. The patient was successfully treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and adjuvant local radiotherapy.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, B-Cell/pathology , Neoplastic Stem Cells/pathology , Nose Neoplasms/pathology , Skin Neoplasms/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Lymphoma, B-Cell/drug therapy , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/pathology , Nose Neoplasms/drug therapy , Prednisone/therapeutic use , Skin Neoplasms/drug therapy , Syndrome , Vincristine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...